The stock of QLT Inc. (USA) (NASDAQ:QLTI) is a huge mover today! The stock increased 6.56% or $0.12 on November 29, hitting $1.95. About 782,954 shares traded hands or 910.09% up from the average. QLT Inc. (USA) (NASDAQ:QLTI) has risen 22.82% since April 26, 2016 and is uptrending. It has outperformed by 17.56% the S&P500.
The move comes after 6 months positive chart setup for the $100.05M company. It was reported on Nov, 29 by Barchart.com. We have $2.05 PT which if reached, will make NASDAQ:QLTI worth $5.00 million more.
Analysts await QLT Inc. (USA) (NASDAQ:QLTI) to report earnings on February, 23. They expect $-0.10 earnings per share, down 66.67% or $0.04 from last year’s $-0.06 per share. After $-0.11 actual earnings per share reported by QLT Inc. (USA) for the previous quarter, Wall Street now forecasts -9.09% EPS growth.
According to Zacks Investment Research, “QLT PhotoTherapeutics Inc. is engaged in the development and commercialization of proprietary pharmaceutical products for use in photodynamic therapy, an emerging field of medicine utilizing light-activated drugs in the treatment of disease. QLT’s innovative science has advanced photodynamic therapy beyond applications in cancer towards potential breakthrough treatments in ophthalmology and autoimmune disease. QLT PhotoTherapeutics Inc. is headquartered in Vancouver, Canada.”
Insitutional Activity: The institutional sentiment decreased to 0.73 in 2016 Q2. Its down 0.13, from 0.86 in 2016Q1. The ratio turned negative, as 7 funds sold all QLT Inc. (USA) shares owned while 15 reduced positions. 7 funds bought stakes while 12 increased positions. They now own 27.34 million shares or 13.89% less from 31.75 million shares in 2016Q1.
Susquehanna Intll Gp Llp last reported 24,706 shares in the company. Farmers Merchants Investments holds 0% of its portfolio in QLT Inc. (USA) (NASDAQ:QLTI) for 958 shares. Tradewinds Ltd Llc accumulated 0% or 50 shares. Toronto Dominion Commercial Bank last reported 0% of its portfolio in the stock. Goldman Sachs Group Incorporated Incorporated reported 498,637 shares or 0% of all its holdings. Moreover, Pnc Svcs Incorporated has 0% invested in QLT Inc. (USA) (NASDAQ:QLTI) for 200 shares. Clear Harbor Asset Management Limited Liability Corp holds 77,725 shares or 0.02% of its portfolio. Wells Fargo Mn accumulated 1,545 shares or 0% of the stock. Barclays Public Limited Co reported 3 shares or 0% of all its holdings. D E Shaw And has 446,692 shares for 0% of their US portfolio. Creative Planning has invested 0% of its portfolio in QLT Inc. (USA) (NASDAQ:QLTI). Walleye Trading Lc holds 800 shares or 0% of its portfolio. California Public Employees Retirement System accumulated 0% or 140,000 shares. Royal Financial Bank Of Canada reported 1,480 shares or 0% of all its holdings. Knott David M accumulated 0% or 545,926 shares.
Insider Transactions: Since September 13, 2016, the stock had 1 buying transaction, and 0 sales for $206,574 net activity. STONEPINE CAPITAL – L.P. bought 133,496 shares worth $206,574.
More notable recent QLT Inc. (USA) (NASDAQ:QLTI) news were published by: Prnewswire.com which released: “QLT announces sale of QLT USA, Inc. for up to US$230 million” on October 01, 2009, also Benzinga.com with their article: “Mid-Afternoon Market Update: Crude Oil Down 3.5%; Thor Industries Shares Surge …” published on November 29, 2016, Businesswire.com published: “Allergan Announces Agreement to Acquire Aczone ® Gel 5%” on June 09, 2008. More interesting news about QLT Inc. (USA) (NASDAQ:QLTI) were released by: Businesswire.com and their article: “InSite Vision to Merge With Canadian Biotechnology Company QLT” published on June 08, 2015 as well as Bioworld.com‘s news article titled: “Auxilium Pharmaceuticals ditches QLT, agrees to $2.6B acquisition by Endo” with publication date: October 10, 2014.
QLTI Company Profile
QLT Inc., incorporated in 1981, is a biotechnology company. The Firm is focused on the development and commercialization of ocular products that address the unmet medical needs of patients and clinicians around the world. The Company’s activities consist of clinical development programs focused on its synthetic retinoid, QLT091001, for the treatment of certain age-related and inherited retinal diseases (IRD) caused by retinal pigment epithelium protein 65 (RPE65) and lecithin: retinol acyltransferase (LRAT) gene mutations. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a biochemical component of the visual retinoid cycle.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.